FY2025 · ended Dec 28, 2025 · Revenue $2.73B, -1.9% YoY · Filed Feb 19, 2026
Quidelortho Corp (QDEL) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Dec 28, 2025, it reported revenue of $2.7 billion and a net loss of $1.1 billion. Free cash flow was -$83.0 million. As of Sep 27, 2026 it held $166.4 million in cash and investments and $603.4 million in total debt.
Revenue (TTM)
$2.59B
-4.5% vs year-ago TTM
Net income (TTM)
$-369.20M
+68.7% vs year-ago TTM
Operating cash flow (TTM)
$7.90M
-78.6% vs year-ago TTM
Free cash flow (TTM)
$-117.10M
+23.9% vs year-ago TTM
EPS (TTM)
$-5.40
+69.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
68.08M
+0.9% vs prior year
Net cash
$-437.00M
as of Sep 27, 2026
Operating margin
-4.9%
FY 2026
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- QDEL (Nasdaq)
- Fiscal year ends
- January 1
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1906324
- Former names
- Coronado Topco, Inc. (until Apr 11, 2022)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 28, 2025 |
FY 2024 Dec 29, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Jan 1, 2023 |
|---|---|---|---|---|
| Revenue | $2.7B | $2.8B | $3.0B | $3.3B |
| Operating income | -$919.2M | -$2.0B | $139.1M | $843.7M |
| Net income | -$1.1B | -$2.1B | -$10.1M | $548.7M |
| Diluted EPS | -$16.69 | -$30.54 | -$0.15 | $9.56 |
| Operating cash flow | $105.2M | $83.0M | $280.2M | $885.3M |
| Free cash flow | -$83.0M | -$112.1M | $70.9M | $744.4M |
| Total assets | $5.8B | $6.4B | $8.6B | $8.9B |
| Total liabilities | $3.8B | $3.4B | $3.6B | $3.9B |
| Stockholders' equity | $1.9B | $3.0B | $5.0B | $4.9B |
| Cash and investments | $169.8M | $98.3M | $174.7M | $366.0M |
| Total debt | $2.9B | $2.7B | $2.6B | $2.9B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 27, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 23, 2026 | Sep 23, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 28, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 23, 2026 | Jun 22, 2026 |
All 502 Quidelortho Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.